Koichi Minato

4.5k total citations · 1 hit paper
171 papers, 3.1k citations indexed

About

Koichi Minato is a scholar working on Oncology, Pulmonary and Respiratory Medicine and Epidemiology. According to data from OpenAlex, Koichi Minato has authored 171 papers receiving a total of 3.1k indexed citations (citations by other indexed papers that have themselves been cited), including 121 papers in Oncology, 103 papers in Pulmonary and Respiratory Medicine and 21 papers in Epidemiology. Recurrent topics in Koichi Minato's work include Lung Cancer Treatments and Mutations (89 papers), Lung Cancer Research Studies (70 papers) and Lung Cancer Diagnosis and Treatment (41 papers). Koichi Minato is often cited by papers focused on Lung Cancer Treatments and Mutations (89 papers), Lung Cancer Research Studies (70 papers) and Lung Cancer Diagnosis and Treatment (41 papers). Koichi Minato collaborates with scholars based in Japan, United States and United Kingdom. Koichi Minato's co-authors include Yuka Fujita, Hisao Imai, Kazuhiko Nakagawa, Kyoichi Kaira, Kunihiko Kobayashi, Akira Inoue, Toshiyuki Harada, Yasuhiro Fujiwara, Akihiko Gemma and Satoshi Morita and has published in prestigious journals such as Journal of Clinical Oncology, SHILAP Revista de lepidopterología and Cancer.

In The Last Decade

Koichi Minato

162 papers receiving 3.0k citations

Hit Papers

Gefitinib Alone Versus Gefitinib Plus Chemotherapy for No... 2019 2026 2021 2023 2019 100 200 300
What are hit papers?

Hit papers significantly outperform the citation benchmark for their cohort. A paper qualifies if it has ≥500 total citations, achieves ≥1.5× the top-1% citation threshold for papers in the same subfield and year (this is the minimum needed to enter the top 1%, not the average within it), or reaches the top citation threshold in at least one of its specific research topics.

  1. Gefitinib Alone Versus Gefitinib Plus Chemotherapy for Non–Small-Cell Lung Cancer With Mutated Epidermal Growth Factor Receptor: NEJ009 Study
    2019 345 citations Yukio Hosomi, Satoshi Morita et al. Journal of Clinical Oncology profile →

Peers — A (Enhanced Table)

Peers by citation overlap · career bar shows stage (early→late) cites · hero ref

Name h Career Trend Papers Cites
Koichi Minato Japan 29 2.1k 1.6k 781 364 306 171 3.1k
Young Hak Kim Japan 30 1.9k 0.9× 1.7k 1.1× 644 0.8× 279 0.8× 225 0.7× 127 2.8k
Sun Min Lim South Korea 27 1.5k 0.7× 1.6k 1.1× 900 1.2× 521 1.4× 216 0.7× 132 2.8k
Hidehito Horinouchi Japan 32 2.0k 1.0× 1.7k 1.1× 497 0.6× 309 0.8× 239 0.8× 225 3.0k
Paolo Bidoli Italy 27 2.0k 1.0× 1.9k 1.2× 531 0.7× 292 0.8× 365 1.2× 127 3.1k
Luís Manso Spain 22 1.9k 0.9× 1.6k 1.0× 710 0.9× 802 2.2× 276 0.9× 153 3.3k
Yukio Hosomi Japan 28 2.5k 1.2× 2.1k 1.3× 878 1.1× 429 1.2× 215 0.7× 189 3.7k
Yuanyuan Zhao China 29 1.9k 0.9× 1.1k 0.7× 558 0.7× 533 1.5× 475 1.6× 162 3.0k
Guanghui Gao China 30 1.5k 0.7× 1.4k 0.9× 811 1.0× 620 1.7× 152 0.5× 86 2.5k
Shinji Atagi Japan 36 3.2k 1.6× 3.3k 2.1× 819 1.0× 430 1.2× 296 1.0× 182 4.5k
Kenzo Soejima Japan 34 1.1k 0.5× 1.5k 1.0× 1.3k 1.6× 523 1.4× 200 0.7× 129 3.0k

Countries citing papers authored by Koichi Minato

Since Specialization
Citations

This map shows the geographic impact of Koichi Minato's research. It shows the number of citations coming from papers published by authors working in each country. You can also color the map by specialization and compare the number of citations received by Koichi Minato with the expected number of citations based on a country's size and research output (numbers larger than one mean the country cites Koichi Minato more than expected).

Fields of papers citing papers by Koichi Minato

Since Specialization
Physical SciencesHealth SciencesLife SciencesSocial Sciences

This network shows the impact of papers produced by Koichi Minato. Nodes represent research fields, and links connect fields that are likely to share authors. Colored nodes show fields that tend to cite the papers produced by Koichi Minato. The network helps show where Koichi Minato may publish in the future.

Co-authorship network of co-authors of Koichi Minato

This figure shows the co-authorship network connecting the top 25 collaborators of Koichi Minato. A scholar is included among the top collaborators of Koichi Minato based on the total number of citations received by their joint publications. Widths of edges represent the number of papers authors have co-authored together. Node borders signify the number of papers an author published with Koichi Minato. Koichi Minato is excluded from the visualization to improve readability, since they are connected to all nodes in the network.

All Works

20 of 20 papers shown
1.
Imai, Hisao, et al.. (2024). Efficacy and safety of naldemedine for opioid-induced constipation in older patients with cancer: a retrospective study. European Journal of Gastroenterology & Hepatology. 36(5). 571–577. 2 indexed citations
2.
3.
Atagi, Shinji, Takashi Daimon, Kyoichi Okishio, et al.. (2023). A randomized phase III study of docetaxel alone versus docetaxel plus S‐1 in patients with previously treated non‐small cell lung cancer: JMTO LC09‐01. Thoracic Cancer. 14(29). 2941–2949. 1 indexed citations
4.
Yamaguchi, Ou, Norimitsu Kasahara, Hiroshi Soda, et al.. (2023). Predictive significance of circulating tumor DNA against patients with T790M-positive EGFR-mutant NSCLC receiving osimertinib. Scientific Reports. 13(1). 20848–20848. 5 indexed citations
5.
6.
Yamada, Tadaaki, Yasuhiro Gotô, Hiroshi Tanaka, et al.. (2023). A phase 2 trial of durvalumab treatment following radiation monotherapy in patients with non-small cell lung cancer ineligible for stage III chemoradiotherapy: The SPIRAL-RT study. European Journal of Cancer. 195. 113373–113373. 8 indexed citations
7.
Tanimura, Keiko, Junji Uchino, Hideharu Kimura, et al.. (2023). Ramucirumab Plus Docetaxel for Patients with Non-small cell Lung Cancer with Brain Metastases: A Multicenter, Open-Label Single-Arm Phase II Trial. The Oncologist. 28(6). 551–e454. 6 indexed citations
8.
Miyauchi, Eisaku, Satoshi Morita, Atsushi Nakamura, et al.. (2022). Updated Analysis of NEJ009: Gefitinib-Alone Versus Gefitinib Plus Chemotherapy for Non–Small-Cell Lung Cancer With Mutated EGFR. Journal of Clinical Oncology. 40(31). 3587–3592. 53 indexed citations
9.
Naito, Tateaki, Junji Uchino, Toru Kojima, et al.. (2022). A multicenter, open‐label, single‐arm study of anamorelin (ONO‐7643) in patients with cancer cachexia and low body mass index. Cancer. 128(10). 2025–2035. 31 indexed citations
10.
Imai, Hisao, Daijiro Kobayashi, Kyoichi Kaira, et al.. (2022). Clinical impact of post-progression survival in patients with locally advanced non-small cell lung cancer after chemoradiotherapy. Radiology and Oncology. 56(2). 228–237. 1 indexed citations
11.
Shimokawa, Mototsugu, Hirotoshi Iihara, Yukiyoshi Fujita, et al.. (2021). Low-Dose Olanzapine Plus Granisetron and Dexamethasone for Carboplatin-Induced Nausea and Vomiting in Patients with Thoracic Malignancies: A Prospective Multicenter Phase II Trial. The Oncologist. 26(6). e1066–e1072. 5 indexed citations
12.
Imai, Hisao, Ryoichi Onozato, Kyoichi Kaira, et al.. (2021). Post-Progression Survival Highly Influences Overall Survival in Driver Gene Mutation/Translocation Negative or Unknown Type of Non-Small Cell Lung Cancer. Oncology. 100(2). 89–100. 1 indexed citations
13.
14.
Kaira, Kyoichi, Reiko Sakurai, Hisao Imai, et al.. (2017). High expression of GRP78/BiP as a novel predictor of favorable outcomes in patients with advanced thymic carcinoma. International Journal of Clinical Oncology. 22(5). 872–879. 13 indexed citations
15.
Kawahara, Masaaki, Shinji Atagi, Kiyoshi Komuta, et al.. (2013). Carboplatin plus either docetaxel or paclitaxel for Japanese patients with advanced non-small cell lung cancer.. PubMed. 33(10). 4631–7. 6 indexed citations
16.
Naito, Yoichi, Satoshi Tsuchiya, Shinichi Ishihara, et al.. (2008). Impact of Preexisting Pulmonary Fibrosis Detected on Chest Radiograph and CT on the Development of Gefitinib-Related Interstitial Lung Disease. American Journal of Clinical Oncology. 31(4). 340–344. 21 indexed citations
17.
Minato, Koichi, et al.. (2006). A Case of Leiomyoma with Lung and Subcutaneous Metastasis. Haigan. 46(4). 379–380. 1 indexed citations
18.
Kaira, Kyoichi, Atsushi Takise, Koichi Minato, et al.. (2005). Phase II study of weekly docetaxel and cisplatin in patients with non-small cell lung cancer. Anti-Cancer Drugs. 16(4). 455–460. 10 indexed citations
19.
Saito, Ryoko, et al.. (1989). Clinical effects of cepharanthin (Ceph.) on leukopenia by chemotherapy in lung cancer patients.. PubMed. 24(11). 2587–93. 13 indexed citations
20.
Nagatani, T, et al.. (1983). [5 Cases of immunoblastic lymphadenopathy (IBL)- like T cell lymphoma-a report on the clinical, histopathological and immunological investigations].. PubMed. 93(4). 421–31.

Rankless uses publication and citation data sourced from OpenAlex, an open and comprehensive bibliographic database. While OpenAlex provides broad and valuable coverage of the global research landscape, it—like all bibliographic datasets—has inherent limitations. These include incomplete records, variations in author disambiguation, differences in journal indexing, and delays in data updates. As a result, some metrics and network relationships displayed in Rankless may not fully capture the entirety of a scholar's output or impact.

Explore authors with similar magnitude of impact

Breakdown of academic impact, for papers by Young Hak Kim Breakdown of academic impact, for papers by Sun Min Lim Breakdown of academic impact, for papers by Hidehito Horinouchi Breakdown of academic impact, for papers by Paolo Bidoli Breakdown of academic impact, for papers by Luís Manso Breakdown of academic impact, for papers by Yukio Hosomi Breakdown of academic impact, for papers by Yuanyuan Zhao Breakdown of academic impact, for papers by Guanghui Gao Breakdown of academic impact, for papers by Shinji Atagi Breakdown of academic impact, for papers by Kenzo Soejima
Rankless by CCL
2026